Tensha Therapeutics

Tensha completes $15 million Seires A financing round

Monday, September 12, 2011

Tensha Therapeutics has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes. The company’s lead program, presently in preclinical development, is a first-in-class small molecule aimed at the treatment of BRD4-NUT midline carcinoma (a rare, invariably fatal cancer), acute myeloid leukemias, multiple myeloma, and other malignancies. HealthCare Ventures is the sole investor in the financing.

[Read More]